Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer
Translational Oncology · 2026-04 · 66 · 102707
DOI: 10.1016/j.tranon.2026.102707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2026-04. Verfasst von Zohreh Taheri Kangarshahi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, NT.C., Islamic Azad University, Tehran, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Breast cancer treatment faces numerous challenges, including drug resistance and lack of precise drug targeting, which reduce therapeutic efficacy. This study investigated the potential use of hydroxyurea (HU), a potent antimetabolite, and exosomes derived from adipose-derived mesenchymal stem cells (AD-MSCs) as natural drug carriers to improve breast cancer therapy. Exosomes were isolated from AD-MSCs and characterized using immunophenotyping and various analytical techniques. HU was subsequently loaded into the exosomes via sonication, and its concentration was quantified by high-performance liquid chromatography (HPLC). Anticancer effects were evaluated through cell viability assays, apoptosis analysis, cell cycle profiling, and real-time PCR assessment of genes related to metastasis and angiogenesis. HU-loaded exosomes (HU-Exo) significantly enhanced cytotoxicity, reducing the IC50 value by up to threefold compared to free HU. HU-Exo also promoted apoptosis, induced S-phase cell cycle arrest, and inhibited migration of 4T1 breast cancer cells. Furthermore, expression of MMP2, MMP9, and VEGF was markedly downregulated. These results suggest that exosomes improve drug uptake and bypass drug resistance mechanisms, enabling dose reduction and minimizing side effects. This study introduces HU-Exo as a targeted and multifaceted drug delivery system capable of inhibiting breast tumor growth and metastasis, paving the way for the development of novel and combination therapies in the future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics, NT.C., Islamic Azad University, Tehran, Iran.
- Department of Molecular Medicine, Medical Biotechnology Institute, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Electronic address: shahla@nigeb.ac.ir.
- Department of Microbiology, NT.C., Islamic Azad University, Tehran, Iran.
- Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Zitieren
APA
Taheri Kangarshahi, Z., Ganji, S. M., Ashrafi, F., & Abbasi, A. (2026). Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer. Translational Oncology, 66, 102707. https://doi.org/10.1016/j.tranon.2026.102707
Vancouver
Taheri Kangarshahi Z, Ganji SM, Ashrafi F, Abbasi A. Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer. Translational Oncology. 2026;66:102707. doi:10.1016/j.tranon.2026.102707
BibTeX
@article{TaheriKangarshahi2026,
author = {Taheri Kangarshahi, Zohreh and Ganji, Shahla Mohammad and Ashrafi, Fatemeh and Abbasi, Ardeshir},
title = {Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer},
journal = {Translational Oncology},
year = {2026},
volume = {66},
pages = {102707},
doi = {10.1016/j.tranon.2026.102707}
}
EUVIMED